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to support consistent reporting of dose-volume data and 
NTCP-models. However, further improvement of delineation 
quality can be achieved by training and education, and a 
more consistent use of these guidelines. References: 1. 
Brouwer et al., Radiother Oncol 2015 aug 13 (ahead of print). 
2. Steenbakkers et al., Int J Radiat Oncol Biol Phys. 
2006;64:435-48. 3. Hanna GG et al., Clin Oncol. 2010;22:515–
525. 
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Locally advanced NSCLC is a heterogeneous disease both with 
regard of the staging and the tumor behavior. In order to 
improve outcome, combinations of radiation (RT) with 
cytotoxic drugs to modulate RT-induced cytotoxicity were 
introduced and are now standard of care. Also in many other 
malignancies combined modality has shown to improve 
outcome and has become standard of care. These treatment 
options are in particular of benefit in patients that can 
tolerate such treatment regimens. Improvements have been 
made both in chemotherapy and the radiotherapy. However, 
co-morbidities and the observed increased normal tissue 
toxicity limit the use of potent chemoradiotherapy 
approaches. In order to enhance the therapeutic window, 
tumor targeted strategies are needed to allow tumor 
radiosensitization while not affecting normal tissue. This 
warrants the evaluation of the potential of novel targeted 
radiosensitizers with tumor targeted properties. The main 
mechanism by which both radiation and cisplatin kill tumor 
cells is by an accumulation of un- or misrepaired DNA 
damage. PARP inhibitors increase radiation and 
chemotherapy (cisplatin) response in preclinical studies 
including lung cancer models. PARP inhibitors have been 
shown to specifically kill homologous recombination deficient 
tumor cells as single agent. ATM mutations are expected to 
affect DSB repair and homologous recombination status 
therefore amplifying damage induced by the combined PARP 
inhibitor radiation treatment. Thus tumor targeted treatment 
and radio-chemosensitization in lung cancer could be 
achieved in the presence of frequently observed ATM gene 
mutations in lung cancer. Olaparib exhibits low systemic 
toxicity profiles when given as monotherapy. When combined 
with cisplatin and RT enhanced toxicity is anticipated, 
necessitating careful dose- and schedule-finding and 
development and validation of supporting pharmacodynamic 
markers. Such approach could also serve as a template for 
other promising radiosensitizers, for example DNA-PK, ATM 
and ATR inhibitors of kinases that are key mediators of the 
so-called DNA damage response (DDR). 
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Increased understanding of the molecular mechanisms 
underlying tumour and normal cell radiosensitivity has led to 
the identification of a variety of potential targets for rational 
intervention. These are based on the “hallmarks of cancer”, 
eight biological capabilities acquired during the multistep 
development of human tumours. Among these, targeting the 
DNA damage response represents an attractive strategy, 
especially in tumours that contain mutations in specific 
components of the DNA repair pathway, such as BRCA1 and 
BRCA2. In addition to their use as single agents, inhibitors of 
the DNA damage response, when combined with radiation 
could increase tumour response while sparing the normal 
tissue. 
Poly(ADP-ribose) polymerase (PARP) inhibitors affect DNA 
repair and thus are good candidates for combined use with 
DNA damaging agents. Indeed, PARP inhibitors increase 
radiation and chemotherapy responses in preclinical studies. 
As a single agent they have been shown to specifically kill 
homologous recombination (HR) deficient tumour cells. A 
large variety of tumour-specific mutations, such as in BRCA or 
ATM, affect double strand break repair and HR status and 
therefore amplify the damage induced by the combined PARP 
inhibitor radiation treatment. We found that the PARP 
inhibitor olaparib induced radiosensitisation in mouse breast 
cancer cells and in a panel of human head and neck cancer 
cell lines at much lower doses than those required for its 
single agent activity. Importantly, at these low doses olaparib 
prevented PAR induction by radiation. Also, the extent of 
radiosensitisation by olaparib depended on the integrity of 
the HR pathway, as witnessed by the difference in olaparib 
dose required to induce radiosensitisation in BRCA2-deficient 
versus BRCA2-complemented cells. 
We have designed 3 phase I-II studies evaluating the safety 
and tolerability of olaparib, in combination with radiotherapy 
in locally advanced breast cancer, non-small cell lung cancer 
and head and neck cancer. Dose-escalation according to the 
TITE-CRM design allows the evaluation of late toxicity and 
ensures continuous patient accrual. In support of these trials, 
biomarkers for the radiosensitisation efficacy of PARP 
inhibitors have been developed and are evaluated. Tumour 
and normal tissue samples are collected from all patients to 
measure PARP inhibition and γH2AX foci formation. These 
measurements will help to guide the dose-escalation strategy 
used in these trials. 
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DNA repair within cancers contributes to radioresistance and 
is a concept across all histology’s. Cancer cells employ rapid 
and efficient methods for repairing damaged single and 
double strand DNA breaks from radiation and chemotherapy. 
Can we take advantage of this survival mechanism? One 
strategy incorporates the use of poly(ADP-ribose) polymerase 
(PARP) inhibitors. What do we know about PARP? PARP 
inhibition sparked interest in oncology based in part on the 
concept of “synthetic lethality” in which cancer cells with 
pre-existing deficiencies in homologous-recombination 
pathways (e.g. BRCA mutations) exhibit highly selective 
cytotoxicity to single agent PARP inhibitors in contrast to 
normal cells – a differentiation that radiation oncologists find 
attractive and might provide an opportunity with radiation 
based studies for locally advanced cancers. Building upon the 
synthetic lethality story, PARP inhibitors show promise as 
radiosensitizers by directly preventing cancer cells from 
repairing stress induced DNA damage. In the preclinical 
setting, our data suggested enhanced sensitivity to PARP(I) 
monotherapy as well as when combined with radiation across 
a variety of HNSCC lines known to be HPV negative many 
groups have shown the ability of PARP inhibitors to sensitize 
a variety of histology’s, both p53 wild type and null, to 
radiation in both in vitro and in vivo settings. The data seems 
to suggest that the levels of PARP inhibition required to 
enhance radiation may be significantly lower than when used 
